Product Description
ABI-1968, a topical cream, in the treatment of cervical precancerous lesions in females without human immunodeficiency virus (HIV) infection. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03697226)
Mechanisms of Action: Apoptosis Stimulant
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Antiva Biosciences
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Kidney Diseases|Pelvic Inflammatory Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ACTRN12619001554156 | P1 |
Recruiting |
Kidney Diseases|Pelvic Inflammatory Disease |
2019-12-01 |
2024-11-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/14/2020 |
News Article |
Cervical Intraepithelial Neoplasia, Pipeline Review, H2 2019 - Bioleaders Corp, Elicio Therapeutics, Novan Inc & Vaccibody AS - ResearchAndMarkets.com |